Sucampo Pharmaceuticals
Defunct pharmaceutical company
From Wikipedia, the free encyclopedia
Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders.[1] In 2018, the company was acquired by Mallinckrodt.
| Industry | Pharmaceutical industry |
|---|---|
| Founded | 1996 |
| Defunct | February 12, 2018 |
| Fate | Acquired by Mallinckrodt |
| Headquarters | Rockville, Maryland |
Key people | Peter Greenleaf (CEO and (Chairman) Andrew P. Smith (CFO) |
| Products | Amitiza |
| Revenue |  $230 million (2016) |
 $18 million (2016) | |
| Total assets | $520 million (2016) |
| Total equity | $167 million (2016) |
Number of employees | 139 (2017) |
| Website | www |
| Footnotes / references [1] | |
Sucampo had two marketed products, Amitiza, which treats constipation issues and Rescula, which helps treat ocular hypertension and open-angle glaucoma. Takeda Pharmaceutical Company had a license to distribute Rescula globally except for in Japan and China. The company had two Phase III drugs in development for rare diseases — one for Niemann-Pick Type C and the other for familial adenomatous polyposis, which can cause colon cancer if untreated.[1]
History
The company was founded by Ryuji Ueno and Sachiko Kuno in 1996.[1]
In January 2006, the company received approval from the Food and Drug Administration for Amitiza.[2]
In 2010, the company entered into arbitration with its partner, Takeda Pharmaceutical Company, claiming that sales of Amitiza floundered because of a half-hearted marketing effort by Takeda. Sucampo lost the arbitration.[3]
In late 2015, the company moved its headquarters from Bethesda, Maryland to Rockville, Maryland.[4]
In January 2016, the company acquired an option for an exclusive license to a drug to treat familial adenomatous polyposis.[5]
In April 2017, the company acquired Vtesse.[6]
In February 2018, the company was acquired by Mallinckrodt. At that time, the founders owned a combined 30% of the company.[7]